Valiance Asset Management

Laminate Medical Technologies is developing a new, external support device for AV fistulas, to be implanted during the fistula creation surgical procedure. The VasQ Device alleviates wall tension and regulates fistula geometry where an undesired narrowing of the vein and/or frequent blockages of the blood vessels may occur during the first year. Use of Laminate Medical Technology’s novel device aims to drive a change in the hemodialysis vascular access treatment paradigm and bring about a significant reduction in the annual fistula failure rate, thereby reducing kidney-failure related complications, re-interventions, and the cost burden of vascular access complications.

MyoScience Inc. engages in development and commercialization of technology driven dermatological products. MyoScience Inc. was founded in 2005 and is headquartered in Redwood City, California.

FEops is a recognized pioneer in the field of physics-based simulations for minimally invasive cardiovascular devices and procedures. They apply this technology from bench to bed, by offering advice to medical device companies as well as to medical specialists and physicians. Their computer simulations have proven to provide medical device developers and manufacturers with unique insights, thereby speeding up R&D processes and supporting device safety. Physicians, for their part, benefit from new patient-specific insights that help them work more efficiently while, most importantly, improving patient safety.

NeoSync is a clinical-stage company with a proprietary platform technology being used to develop advanced, non-invasive neuromodulation products designed to treat Major Depressive Disorder and other diseases of the Central Nervous System .(Autism, Parkinson's Disease, Anxiety, Post Traumatic Stress Disorder, etc.). ​The Company is led by experienced medical device executives and entrepreneurs.

JenaValve Technology, Inc. is a medical device company focused on the design, development, and commercialization of innovative transcatheter heart valve solutions for the treatment of patients suffering from heart valve disease. The Company’s Trilogy™ Heart Valve System is a transcatheter aortic valve replacement (“TAVR”) system designed to treat patients with symptomatic, severe aortic regurgitation (“AR”) and aortic stenosis (“AS”) in high surgical risk patients. The Trilogy System received CE Mark approval in May 2021, providing European physicians, for the first time, a device with true dual-disease treatment capabilities. JenaValve received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) to facilitate the review of ALIGN-AR, a pivotal trial in the U.S., as part of its premarket approval (“PMA”) application for the Trilogy Heart Valve System for the treatment of symptomatic, severe aortic regurgitation (AR) in high surgical risk patients. If approved, Trilogy would become the first and only TAVR system in the U.S. to be indicated for the treatment of AR patients. JenaValve is headquartered in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany. Additional information is available at www.jenavalve.com. US: CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use.

Biocartis SA, a molecular diagnostics company, develops diagnostics technology platform for multiplexed detection of bio-analytes. It focuses on integrated molecular and immunodiagnostics based on its proprietary micro-technology platform. The company develops and licenses a series of technologies to build a diagnostics platform for multiplexed detection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. Its products are used for various applications, including analysis of bio-molecules associated with risks factors, early detection, staging, treatment selection, and monitoring of a disease. Biocartis SA was founded in 2007 and is based in Lausanne, Switzerland.

MyoScience Inc. engages in development and commercialization of technology driven dermatological products. MyoScience Inc. was founded in 2005 and is headquartered in Redwood City, California.

MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients.

Biocartis SA, a molecular diagnostics company, develops diagnostics technology platform for multiplexed detection of bio-analytes. It focuses on integrated molecular and immunodiagnostics based on its proprietary micro-technology platform. The company develops and licenses a series of technologies to build a diagnostics platform for multiplexed detection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. Its products are used for various applications, including analysis of bio-molecules associated with risks factors, early detection, staging, treatment selection, and monitoring of a disease. Biocartis SA was founded in 2007 and is based in Lausanne, Switzerland.